Exicure Inc Stock Price, News & Analysis

Coya Therapeutics, a clinical-stage biotechnology company, has appointed David S. Snyder as Chief Financial Officer and Chief Operating Officer. Snyder, with over 25 years of experience, will contribute significantly to the company’s financial management and assist in potential public offerings. Previous roles include CFO of Exicure and Cellular Dynamics. Coya focuses on innovative therapies for neurodegenerative and autoimmune diseases using regulatory T cells and exosome therapeutics. The company aims to address significant unmet medical needs with its advanced clinical pipeline.

Exicure, Inc. (NASDAQ: XCUR) reported a significant net loss of $64.1 million for 2021, up from $24.7 million in 2020, driven by decreased non-cash revenue and higher R&D expenses totaling $49.0 million. Revenue decreased to $(0.5) million from $16.6 million in 2020, largely due to changes in the AbbVie collaboration. As of December 31, 2021, cash reserves amounted to $48.3 million. The company anticipates reporting results from initial SCN9A in vivo studies by year-end 2022 and is focused on strategic partnerships and out-licensing opportunities in 2022.

Exicure, Inc. (NASDAQ: XCUR) has announced significant management changes. Brian C. Bock will resign as President and CEO, transitioning to a Special Advisor role effective immediately. Dr. Matthias Schroff, previously Chief Scientific Officer, will take over as President and CEO on February 4, 2022. Additionally, several Board members, including Timothy P. Walbert and Andrew Sassine, are resigning. Dr. Betsy Garofalo is appointed as Chair of the Board. These changes aim to streamline leadership and enhance operational efficiency in advancing Exicure's gene therapy programs.

Exicure, Inc. (NASDAQ:XCUR) has announced a definitive agreement with institutional investors for a registered direct offering of 34,576,068 shares of common stock at $0.3326 each, plus warrants to purchase another 17,288,034 shares at an exercise price of $0.2701. The expected gross proceeds are about $11.5 million, intended for working capital and corporate purposes. The offering is set to close around December 16, 2021, subject to customary conditions. H.C. Wainwright serves as the exclusive placement agent.

Exicure (NASDAQ: XCUR) announced a 50% workforce reduction and the wind-down of its cavrotolimod and XCUR-FXN programs. The Audit Committee's investigation revealed that former employee Grant Corbett misreported data related to these programs from 2020 to 2021. The company will focus on preclinical programs targeting SCN9A for pain and partnered projects with Ipsen and AbbVie, estimating $6 million in 2022 cost savings and incurring $1.2 million in restructuring expenses.

Exicure, Inc. (NASDAQ: XCUR) reported Q3 2021 results, revealing a net loss of $23.5 million, up from $8.8 million in Q3 2020. R&D expenses surged to $16.5 million, reflecting increased headcount from 48 to 65. Cash reserves rose to $62 million from $57.3 million. Despite a strategic partnership with Ipsen yielding $20 million upfront, the company faces uncertainty due to an ongoing investigation into alleged improprieties related to its XCUR-FXN program. The Phase 1b/2 trial of cavrotolimod is enrolling patients, but results are postponed to H2 2022 due to COVID-19 delays.

Exicure, Inc. (NASDAQ: XCUR) has filed a Form 12b-25 with the SEC, delaying its Q3 2021 10-Q Report due to an ongoing internal investigation prompted by claims of impropriety from a former senior researcher regarding the XCUR-FXN program for Friedreich’s ataxia. The Audit Committee has engaged external counsel for the investigation, and the company is unable to predict its duration or outcome. Exicure aims to submit the 10-Q within five days after the original due date. The firm develops therapies using its proprietary SNA technology for various medical conditions, including neurological disorders.

Exicure, a biotechnology company focused on gene therapy, announced its participation in two significant scientific conferences in November 2021. At TIDES EU, Bart Anderson will present on the development of Spherical Nucleic Acids targeting SCN9A for neuropathic pain on November 16. Additionally, at Neuroscience 2021, presentations will include research on Spherical Nucleic Acids targeting frataxin in Friedreich’s ataxia and their biodistribution in mouse models. Exicure is advancing its therapeutic candidates, including XCUR-FXN for Friedreich’s ataxia and cavrotolimod for advanced solid tumors.

Exicure, Inc. (NASDAQ: XCUR), a biotechnology company specializing in gene regulatory and immunotherapeutic drugs, has announced its participation in two scientific conferences this October. The 17th International Congress on Neuronal Ceroid Lipofuscinosis will feature a presentation on Spherical Nucleic Acids targeting CLN3 for Batten Disease by Grant Corbett on October 8, 2021. Additionally, the International Oligonucleotides and Peptides Conference will see Matthias Schroff discussing their technology on October 18, 2021. Exicure focuses on innovative treatments for various neurological and genetic disorders.